About Raymond Pirtle
Form D filings for Amytrx Therapeutics from 2016 to 2024 list Raymond Pirtle as director.
Raymond Pirtle first appears on SEC filings in 2016.
Experience
This experience comes from SEC filings. The years are when the filings name Raymond Pirtle in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Raymond Pirtle works with at each company, as listed on that company's latest Form D.
Amytrx Therapeutics, Inc. · Form D, Jan 31, 2024
MG
Matthew Gonda
President and CEO, director
LG
Lawrence Greer
Director
SJ
Satish Joshi
Director
MH
Michael Howell
Director
DC
Dennis Carlo
Director